Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Basimglurant SCHEMBL29377966 | 0.88 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| Basimglurant SCHEMBL560590 | 0.88 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4630072 | 0.85 | GRM5 (0.58) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608527 | 0.78 | GRM5 (0.83) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607722 | 0.78 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607411 | 0.78 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607932 | 0.75 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608562 | 0.75 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607850 | 0.75 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609394 | 0.75 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | claimed |
| EP-1606277-B1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | claimed |
| US-7153874-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-26 | — | — | US | claimed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20230277513-A1 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | NOEMA PHARMA AG (CH) | 2023-09-07 | — | — | US | disclosed |
| US-11684613-B2 | Methods of treatment of tuberous sclerosis complex | NOEMA PHARMA AG (CH) | 2023-06-27 | — | — | US | disclosed |
| US-20230172922-A1 | METHODS OF TREATMENT OF TRIGEMINAL NEURALGIA | NOEMA PHARMA AG (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1606277-B1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7153874-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277513-A1 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | GRM5, GRIK5, GRM2 | GRM5 1/4885KCNH2 2057/4885ADRB3 1486/4885 |
| US-11684613-B2 | Methods of treatment of tuberous sclerosis complex | GRM5, GRIK5, GRM2 | GRM5 1/4885KCNH2 2057/4885ADRB3 1486/4885 |
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | GRM5 10/4885KCNH2 393/4885ADRB3 918/4885 |
| US-20230172922-A1 | METHODS OF TREATMENT OF TRIGEMINAL NEURALGIA | GRM5, GRIK5, GPR18 | GRM5 1/4885KCNH2 679/4885ADRB3 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.